Ayoğlu H, Altunkaya H, Ozer Y, Yapakçi O, Cukdar G, Ozkoçak I
Department of Anesthesiology and Reanimation, Zonguldak Karaelmas University School of Medicine, Zonguldak, Turkey.
Eur J Anaesthesiol. 2007 Jun;24(6):541-5. doi: 10.1017/S0265021506002250. Epub 2007 Jan 23.
This prospective, double-blind, randomized, placebo-controlled study was designed to determine the efficacy of dexmedetomidine compared with lidocaine in reducing the pain of propofol and rocuronium injection pain.
One hundred and fifty patients, scheduled for elective surgery with general anaesthesia, were divided into five groups: saline (Group 1), dexmedetomidine 0.25 microg kg(-1) (Group 2), lidocaine 0.5 mg kg(-1) (Group 3), dexmedetomidine 0.25 microg kg(-1) plus lidocaine 0.25 mg kg(-1) (Group 4) or dexmedetomidine 0.25 microg kg(-1) plus lidocaine 0.5 mg kg(-1) (Group 5) were administered at a rate of 0.5 mL s(-1) after tourniquet application. The occlusion was released after 1 min and 5 mL of propofol was injected over 20 s. Pain was evaluated by use of a 10-point verbal analogue scale. Then, the rest of the induction dose of propofol, 3 mL of saline bolus and 0.6 mg kg(-1) of rocuronium, was injected. The response to injection of rocuronium was assessed with a four-point scale (0-3).
Groups 1 and 2 were found to have higher propofol injection pain scores than Groups 3, 4 and 5 (P < 0.05). When the study groups were compared according to the overall incidence of withdrawal movements due to rocuronium (1 response) in Groups 1, 2, 3, 4 and 5, they were different (86.7%, 60%, 36.7%, 50% and 40%, respectively) (P < 0.05). Except Group 1, there was no significant difference between the groups according to incidence of withdrawal movement after rocuronium injection (P = 0.325).
Pretreatment with dexmedetomidine is not effective in reducing injection pain of propofol, but may attenuate the hand withdrawal associated to rocuronium, as lidocaine does.
本前瞻性、双盲、随机、安慰剂对照研究旨在确定右美托咪定与利多卡因相比在减轻丙泊酚和罗库溴铵注射痛方面的疗效。
150例计划接受全身麻醉择期手术的患者被分为五组:生理盐水组(第1组)、右美托咪定0.25μg·kg⁻¹组(第2组)、利多卡因0.5mg·kg⁻¹组(第3组)、右美托咪定0.25μg·kg⁻¹加利多卡因0.25mg·kg⁻¹组(第4组)或右美托咪定0.25μg·kg⁻¹加利多卡因0.5mg·kg⁻¹组(第5组)。在使用止血带后以0.5mL·s⁻¹的速度给药。1分钟后松开止血带,并在20秒内注射5mL丙泊酚。使用10分数字评分量表评估疼痛。然后,注射其余诱导剂量的丙泊酚、3mL生理盐水推注和0.6mg·kg⁻¹的罗库溴铵。用四点量表(0 - 3)评估对罗库溴铵注射的反应。
发现第1组和第2组的丙泊酚注射痛评分高于第3组、第4组和第5组(P < 0.05)。当根据第1组、第2组、第3组、第4组和第5组中因罗库溴铵引起的退缩动作(1级反应)的总体发生率对研究组进行比较时,它们有所不同(分别为86.7%、60%、36.7%、50%和40%)(P < 0.05)。除第1组外,根据罗库溴铵注射后退缩动作发生率,各组之间无显著差异(P = 0.325)。
右美托咪定预处理在减轻丙泊酚注射痛方面无效,但可能像利多卡因一样减轻与罗库溴铵相关的手部退缩。